Rasagiline is the second selective MAO-B inhibitor to be approved for the treatment of Parkinson’s disease (PD), and differs from the other existing inhibitor, selegiline, in not being metabolized to amphetamines. This evidence concerns the gene MAOB and Parkinson disease.